Veza, the Data Security Platform Built on the Power of Authorization, Announces Blackstone as a Customer and Strategic Series C Investor
22.6.2022 19:00:00 EEST | Business Wire | Press release
Veza, the data security platform built on the power of authorization, announced an investment in their Series C funding round from Blackstone Innovations Investments, along with participation from previous investors. To date, Veza has raised a total of $110 million from top-tier investors including Accel, Bain Capital, Ballistic Ventures, GV, Norwest Venture Partners, True Ventures, and others. Blackstone has also selected Veza to help modernize its data security and access governance.
Veza empowers organizations to address today’s greatest cybersecurity challenge: who can and should take what action on what data. As the world increasingly moves online, our changing behaviors are driving a transformational shift toward multi-cloud data systems, apps, computing, and infrastructure. This shift creates a complex, distributed web of human identities, accounts, apps, services, and access points that are constantly changing and susceptible to vulnerabilities. To address this, Veza takes a comprehensive approach that pulls together authorization data from disparate systems, giving customers a single source of truth to manage data access and controls.
“Having a world-class cybersecurity program that protects our brand, reputation, investors and intellectual property is of paramount importance to our firm, and we are continuing to incorporate innovative technology solutions,” says Adam Fletcher, Chief Security Officer at Blackstone. “Our team is always looking for ways to develop a more comprehensive view of access across all of our applications and cloud infrastructure to allow us to modernize the firm’s access controls. We are excited to partner with Veza to help us accomplish this.”
“Blackstone Innovations Investments is committed to investing in cutting-edge technology companies that we believe will have a meaningful impact on Blackstone, our portfolio companies, and the broader industry. We look forward to working with Veza and their impressive leadership team as they enter this next phase of growth,” comments Stevi Petrelli, Head of Blackstone Innovations Investments.
“Institutions across multiple industries view Blackstone as an example of exceptional technology deployment and cybersecurity expertise,” says Tarun Thakur, CEO and Co-Founder of Veza. “Veza has greatly benefited from Blackstone’s product feedback and market insights. We are thrilled to work with Blackstone’s Security team to further modernize data security for their hybrid and multi-cloud environment.”
Additional investment in Veza comes from notable entrepreneurs including Dheeraj Pandey, Co-founder & CEO, DevRev and former CEO, Nutanix, and Lars Dalgaard, Founder Luv Ventures, Founder & Former CEO, SuccessFactors.
“Authorization is the source of truth when it comes to understanding who has access to what,” says Dheeraj Pandey, Co-Founder and CEO of DevRev. “Understanding authorization at scale is one of the hardest problems to address and I am excited to watch team Veza bring on a new era of identity, rooted in authorization. Veza is defining authorization as a standard for protecting data against ransomware and other forms of data breach.”
“Entrepreneurs will tell you that company building is one of the hardest, yet rewarding experiences, with real potential to make an impact,” says Lars Dalgaard, Founder Luv Ventures, Founder & Former CEO SuccessFactors. “When evaluating any company, I look for deep technical breakthrough for a massive market opportunity, deal composition and company traction, and passion amongst founders. And, I’m very excited to be partnering with Tarun and Veza on the mission to build an iconic company that will revolutionize the data security industry for decades to come.”
About Veza
Veza is the data security platform built on the power of authorization. Our platform is purpose-built for hybrid multi-cloud environments to help you use and share your data safely. Veza makes it easy to understand, manage, and control who can and should take what action on what data. We organize authorization metadata across identity providers, data systems, cloud service providers, and applications — all to address the toughest data security challenges of the modern era. Founded in 2020, the company is funded by top-tier investors including Accel, Bain Capital, Ballistic Ventures, Blackstone, GV, Norwest Venture Partners, and True Ventures. To learn more, please visit us at veza.com. Many Fortune 500, Fortune 1000 and smaller organizations use its data security platform for protection against ransomware, modernizing access governance for critical data and apps, and implementing data lake security for Snowflake and other solutions. Follow Veza on LinkedIn or on Twitter @vezainc.
About Blackstone
Blackstone is the world’s largest alternative asset manager. We seek to create positive economic impact and long-term value for our investors, the companies we invest in, and the communities in which we work. We do this by using extraordinary people and flexible capital to help companies solve problems. Our $915 billion in assets under management include investment vehicles focused on private equity, real estate, public debt and equity, infrastructure, life sciences, growth equity, opportunistic, non-investment grade credit, real assets and secondary funds, all on a global basis. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, Twitter, and Instagram.
Learn more about Veza:
Get started with Veza Free Trial
Veza for Snowflake Access Governance
Modernize Privileged Access for Data
Explore Veza’s Open Authorization API (OAA) for SaaS applications (GitHub, and more)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220622005641/en/
Contact information
Media Contacts
Teju Shyamsundar
tshyamsundar@veza.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
